Medical Oncology最新文献_第9页

Moscatilin, a potential therapeutic agent for cancer treatment: insights into molecular mechanisms and clinical prospects. 麝香草苷--一种潜在的癌症治疗药物：对分子机制和临床前景的见解。

IF 2.8 4区医学

Medical Oncology Pub Date : 2024-08-17 DOI: 10.1007/s12032-024-02467-6

Rita Silva-Reis, Vera L M Silva, Susana M Cardoso, Izabela Michalak, Mirosława Püsküllüoğlu, Daniela Calina, Javad Sharifi-Rad

{"title":"Moscatilin, a potential therapeutic agent for cancer treatment: insights into molecular mechanisms and clinical prospects.","authors":"Rita Silva-Reis, Vera L M Silva, Susana M Cardoso, Izabela Michalak, Mirosława Püsküllüoğlu, Daniela Calina, Javad Sharifi-Rad","doi":"10.1007/s12032-024-02467-6","DOIUrl":"10.1007/s12032-024-02467-6","url":null,"abstract":"Moscatilin, a bibenzyl derivative from the Dendrobium genus, has been traditionally used in Chinese medicine. Recent studies suggest its potential as a powerful anticancer agent due to its diverse pharmacological properties.This review aims to consolidate current research on moscatilin's anticancer mechanisms, structure-activity relationships, and therapeutic potential to assess its viability for clinical use. A literature search was performed in PubMed/MedLine, Scopus, and Web of Science.The search focused on \"cancer,\" \"moscatilin,\" \"anticancer,\" \"bioactivity,\" \"dendrobium,\" and \"pharmacological properties.\" Relevant studies on molecular mechanisms, preclinical and clinical efficacy, and bioavailability were reviewed. Moscatilin exhibits significant anticancer effects in lung, breast, colorectal, and pancreatic cancers. It induces apoptosis via the JNK/SAPK pathway, inhibits cell proliferation, and suppresses metastasis. Structure-activity relationship studies reveal that phenolic groups and a two-carbon bridge are crucial for its efficacy. Additionally, moscatilin shows good bioavailability and a favorable safety profile, with low toxicity to healthy cells. Moscatilin demonstrates considerable potential as an anticancer agent, targeting multiple cancer progression pathways. Further clinical trials are essential to confirm its therapeutic efficacy and safety in humans.","PeriodicalId":18433,"journal":{"name":"Medical Oncology","volume":null,"pages":null},"PeriodicalIF":2.8,"publicationDate":"2024-08-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141996071","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Cancer/testis antigen expression and co-expression patterns in gastroesophageal adenocarcinoma. 胃食管腺癌中癌症/睾丸抗原的表达和共表达模式

IF 2.8 4区医学

Medical Oncology Pub Date : 2024-08-14 DOI: 10.1007/s12032-024-02475-6

Sukumar Kalvapudi, Akhil Goud Pachimatla, R J Seager, Jeffrey Conroy, Sarabjot Pabla, Sarbajit Mukherjee

{"title":"Cancer/testis antigen expression and co-expression patterns in gastroesophageal adenocarcinoma.","authors":"Sukumar Kalvapudi, Akhil Goud Pachimatla, R J Seager, Jeffrey Conroy, Sarabjot Pabla, Sarbajit Mukherjee","doi":"10.1007/s12032-024-02475-6","DOIUrl":"10.1007/s12032-024-02475-6","url":null,"abstract":"Gastroesophageal adenocarcinoma (GEAC) poses a significant challenge due to its poor prognosis and limited treatment options. Recently, Cancer/testis antigens (CTAs) have emerged as potential therapy targets due to their high expression in tumor cells and their immunogenic nature. We aimed to explore the expression and co-expression of CTAs in GEAC. We analyzed 63 GEAC patients initially and validated our findings in 329 patients from The Cancer Genome Atlas (TCGA) database. CTA expression was measured after RNA sequencing, while clinical information, including survival outcomes and treatment details, was collected from an institutional database. Co-expression patterns among CTAs were determined using Spearman correlation analysis. The majority of the study cohort were male (87%), Caucasian (94%), and had stage IV disease (64%). CTAs were highly prevalent, ranging from 58 to 19%. The MAGE gene family showed the highest expression, consistent across both cohorts. The correlation matrix revealed a distinct cluster of significantly co-expressed genes, including MAGEA3, NY-ESO-1, and others (0.27 ≤ r ≤ 0.73). Survival analysis revealed that individual CTAs were associated with poorer survival outcomes in patients not receiving immunotherapy while showing potential for improved survival in those undergoing immunotherapy, although these findings lacked robust reliability. Our study provides a comprehensive characterization of CTA expression and co-expression in GEAC. The strong correlation among CTAs like MAGE, NY-ESO-1, and GAGE suggests a potential for therapies targeting multiple CTAs simultaneously. Further research, including prospective trials, is warranted to assess the prognostic value of CTAs and their suitability as therapeutic targets.","PeriodicalId":18433,"journal":{"name":"Medical Oncology","volume":null,"pages":null},"PeriodicalIF":2.8,"publicationDate":"2024-08-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11324668/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141982696","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Letters to editor regarding the article "P4HA2 contributes to head and neck squamous cell carcinoma progression and EMT through PI3K/AKT signaling pathway". 致编辑的信，内容涉及文章 "P4HA2通过PI3K/AKT信号通路促进头颈部鳞状细胞癌的进展和EMT"。

IF 2.8 4区医学

Medical Oncology Pub Date : 2024-08-13 DOI: 10.1007/s12032-024-02436-z

K L G Afeeza, S Balachandran, S Muthamizh, E Dilipan

{"title":"Letters to editor regarding the article \"P4HA2 contributes to head and neck squamous cell carcinoma progression and EMT through PI3K/AKT signaling pathway\".","authors":"K L G Afeeza, S Balachandran, S Muthamizh, E Dilipan","doi":"10.1007/s12032-024-02436-z","DOIUrl":"10.1007/s12032-024-02436-z","url":null,"abstract":"We have read the original article titled \"P4HA2 contributes to head and neck squamous carcinoma progression and EMT through PI3K/AKT signaling pathway\" by Yan-Ling Wu et al., which was published in the Medical Oncology journal, with great interest. This study provides valuable insights into the involvement of P4HA2 in the progression of head and neck squamous cell carcinoma (HNSCC), highlighting its potential as an oncogenic factor that promotes epithelial-mesenchymal transition (EMT), motility, invasion, and proliferation of cancer cells through the PI3K/AKT signaling pathway. While this work enhances our understanding of the role of P4HA2 in HNSCC, there are certain aspects that remain unexplored. These areas could be further investigated in future research to obtain a more comprehensive understanding. Specifically, the study did not investigate other signaling pathways or molecular mechanisms through which P4HA2 may impact the development of HNSCC. By exploring these molecular pathways, it may be possible to identify specific targets for pharmaceutical intervention to inhibit the production of P4HA2. Examining these aspects in future research would significantly contribute to our understanding of the role of P4HA2 in HNSCC and its potential as a therapeutic target. We appreciate the authors for their significant contribution and eagerly await future studies that expand upon these findings.","PeriodicalId":18433,"journal":{"name":"Medical Oncology","volume":null,"pages":null},"PeriodicalIF":2.8,"publicationDate":"2024-08-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141971372","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Therapeutic response and safety of radioligand therapy with ¹⁷⁷Lu-PSMA-617 in metastatic castration-resistant prostate cancer patients. 用 177Lu-PSMA-617 对转移性阉割耐药前列腺癌患者进行放射性配体治疗的治疗反应和安全性。

IF 2.8 4区医学

Medical Oncology Pub Date : 2024-08-13 DOI: 10.1007/s12032-024-02466-7

Wardah Ashfaq, Khurram Rehman, Abubaker Shahid, Muhammad Numair Younis

引用次数: 0

Diverse roles of aldolase enzymes in cancer development, drug resistance and therapeutic approaches as moonlighting enzymes. 醛缩酶作为兼职酶在癌症发展、抗药性和治疗方法中的多种作用。

IF 2.8 4区医学

Medical Oncology Pub Date : 2024-08-09 DOI: 10.1007/s12032-024-02470-x

Fan Tang, Qingyang Cui

引用次数: 0

Impact of microRNA variants on PI3K/AKT signaling in triple-negative breast cancer: comprehensive review. 微RNA变异对三阴性乳腺癌PI3K/AKT信号转导的影响：综合综述。

IF 2.8 4区医学

Medical Oncology Pub Date : 2024-08-09 DOI: 10.1007/s12032-024-02469-4

Ehsan Mehrtabar, Amirreza Khalaji, Mojtaba Pandeh, Aram Farhoudian, Nadia Shafiee, Atefe Shafiee, Fatemeh Ojaghlou, Parinaz Mahdavi, Mehdi Soleymani-Goloujeh

{"title":"Impact of microRNA variants on PI3K/AKT signaling in triple-negative breast cancer: comprehensive review.","authors":"Ehsan Mehrtabar, Amirreza Khalaji, Mojtaba Pandeh, Aram Farhoudian, Nadia Shafiee, Atefe Shafiee, Fatemeh Ojaghlou, Parinaz Mahdavi, Mehdi Soleymani-Goloujeh","doi":"10.1007/s12032-024-02469-4","DOIUrl":"10.1007/s12032-024-02469-4","url":null,"abstract":"Breast cancer (BC) is a significant cause of cancer-related mortality, and triple-negative breast cancer (TNBC) is a particularly aggressive subtype associated with high mortality rates, especially among younger females. TNBC poses a considerable clinical challenge due to its aggressive tumor behavior and limited therapeutic options. Aberrations within the PI3K/AKT pathway are prevalent in TNBC and correlate with increased therapeutic intervention resistance and poor outcomes. MicroRNAs (miRs) have emerged as crucial PI3K/AKT pathway regulators influencing various cellular processes involved in TNBC pathogenesis. The levels of miRs, including miR-193, miR-4649-5p, and miR-449a, undergo notable changes in TNBC tumor tissues, emphasizing their significance in cancer biology. This review explored the intricate interplay between miR variants and PI3K/AKT signaling in TNBC. The review focused on the molecular mechanisms underlying miR-mediated dysregulation of this pathway and highlighted specific miRs and their targets. In addition, we explore the clinical implications of miR dysregulation in TNBC, particularly its correlation with TNBC prognosis and therapeutic resistance. Elucidating the roles of miRs in modulating the PI3K/AKT signaling pathway will enhance our understanding of TNBC biology and unveil potential therapeutic targets. This comprehensive review aims to discuss current knowledge and open promising avenues for future research, ultimately facilitating the development of precise and effective treatments for patients with TNBC.","PeriodicalId":18433,"journal":{"name":"Medical Oncology","volume":null,"pages":null},"PeriodicalIF":2.8,"publicationDate":"2024-08-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141906986","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Unveiling the potency of FDA-approved oxidopamine HBr for cervical cancer regulation and replication proteins. 揭示 FDA 批准的氧化胺 HBr 对宫颈癌调节和复制蛋白的功效。

IF 2.8 4区医学

Medical Oncology Pub Date : 2024-08-09 DOI: 10.1007/s12032-024-02462-x

Nawal Helmi, Abdullah Hamadi, Osama M Al-Amer, Hassan A Madkhali, Atif Abdulwahab A Oyouni, Amany I Alqosaibi, Jawaher Almulhim, Rashed Mohammed Alghamdi, Israa J Hakeem, Misbahuddin M Rafeeq

{"title":"Unveiling the potency of FDA-approved oxidopamine HBr for cervical cancer regulation and replication proteins.","authors":"Nawal Helmi, Abdullah Hamadi, Osama M Al-Amer, Hassan A Madkhali, Atif Abdulwahab A Oyouni, Amany I Alqosaibi, Jawaher Almulhim, Rashed Mohammed Alghamdi, Israa J Hakeem, Misbahuddin M Rafeeq","doi":"10.1007/s12032-024-02462-x","DOIUrl":"10.1007/s12032-024-02462-x","url":null,"abstract":"Cervical Cancer remains a women's health concern worldwide and ranks among the most prevalent cancers, particularly in developing countries. Many women are diagnosed with cervical cancer, with a substantial number succumbing to the disease even after the availability of vaccines and drugs. The tumour microenvironment often exhibits immune evasion, including suppression of T-cell activity and altered cytokine, impacting the efficacy of therapeutic interventions and highlighting the need for treatments to modulate the immune response. Despite efforts to promote HPV vaccination and regular screenings, it causes many deaths, underscoring the urgent need for continued research, healthcare access, and rapid drug development or repurposing. In this study, we identified various proteins involved in cervical cancer cell cycle regulation and DNA replication proteins, performed the multitargeted docking with an FDA-approved library, and identified Oxidopamine HBr as a multitargeted drug. Studies extended with pharmacokinetics and compared with the standard values followed by DFT, which supported the compound as a multitargeted inhibitor. Further, the docked complexes were taken for the interaction fingerprints, and it was identified that there are many 9 polar, 5 hydrophobic, 2 aromatic, and 2 basic residues. We extended our studies for 100ns MD Simulation in water, and the computations explored the deviation and fluctuations under 2Å and many intermolecular interactions; the same trajectory files were used for the MMGBSA studies. All the studies have supported the Oxidopamine HBr as a cervical cancer multitargeted inhibitor-however, experimental studies are needed before human use.","PeriodicalId":18433,"journal":{"name":"Medical Oncology","volume":null,"pages":null},"PeriodicalIF":2.8,"publicationDate":"2024-08-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141907042","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Emerging roles of the chromatin remodeler MORC2 in cancer metabolism. 染色质重塑剂 MORC2 在癌症代谢中的新作用。

IF 2.8 4区医学

Medical Oncology Pub Date : 2024-08-08 DOI: 10.1007/s12032-024-02464-9

Bibhukalyan Mohapatra, Suresh B Pakala

引用次数: 0

Doxorubicin downregulates cell cycle regulatory hub genes in breast cancer cells. 多柔比星可下调乳腺癌细胞的细胞周期调控中枢基因。

IF 2.8 4区医学

Medical Oncology Pub Date : 2024-08-08 DOI: 10.1007/s12032-024-02468-5

Mano Chitra Karthikeyan, Chandhru Srinivasan, Kowsika Prabhakar, Priyadharshini Manogar, Abirami Jayaprakash, Antony Joseph Velanganni Arockiam

{"title":"Doxorubicin downregulates cell cycle regulatory hub genes in breast cancer cells.","authors":"Mano Chitra Karthikeyan, Chandhru Srinivasan, Kowsika Prabhakar, Priyadharshini Manogar, Abirami Jayaprakash, Antony Joseph Velanganni Arockiam","doi":"10.1007/s12032-024-02468-5","DOIUrl":"10.1007/s12032-024-02468-5","url":null,"abstract":"Breast cancer (BC) is the leading commonly diagnosed cancer in the world, with complex mechanisms underlying its development. There is an urgent need to enlighten key genes as potential therapeutic targets crucial to advancing BC treatment. This study sought to investigate the influence of doxorubicin (DOX) on identified key genes consistent across numerous BC datasets obtained through bioinformatic analysis. To date, a meta-analysis of publicly available coding datasets for expression profiling by array from the Gene Expression Omnibus (GEO) has been carried out. Differentially Expressed Genes (DEGs) identified using GEO2R revealed a total of 23 common DEGs, including nine upregulated genes and 14 downregulated genes among the datasets of three platforms (GPL570, GPL6244, and GPL17586), and the commonly upregulated DEGs, showed significant enrichment in the cell cycle in KEGG analysis. The top nine genes, NUSAP1, CENPF, TPX2, PRC1, ANLN, BUB1B, AURKA, CCNB2, and CDK-1, with higher degree values and MCODE scores in the cytoscape program, were regarded as hub genes. The hub genes were activated in disease states commonly across all the subclasses of BC and correlated with the unfavorable overall survival of BC patients, as verified by the GEPIA and UALCAN databases. qRT-PCR confirmed that DOX treatment resulted in reduced expression of these genes in BC cell lines, which reinforces the evidence that DOX remains an effective drug for BC and suggests that developing modified formulations of doxorubicin to reduce toxicity and resistance, could enhance its efficacy as an effective therapeutic option for BC.","PeriodicalId":18433,"journal":{"name":"Medical Oncology","volume":null,"pages":null},"PeriodicalIF":2.8,"publicationDate":"2024-08-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141902215","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Cabazitaxel as a promising therapy for cisplatin-resistant bladder cancer: a preliminary study. 卡巴他赛是一种治疗顺铂耐药膀胱癌的有效疗法：一项初步研究。

IF 2.8 4区医学

Medical Oncology Pub Date : 2024-08-06 DOI: 10.1007/s12032-024-02461-y

Asim Joshi, Abantika Ghosh, Prashant Rai, Sarika Tilwani, Venkataramanan Ramachandran, Kumar Prabhash, Mahul Amin, Prashant Kumar

引用次数: 0